J 2047 NY Passed One Chamber
Memorializing Governor Kathy Hochul to proclaim June 9, 2026, as FSGS Awareness Day in the State of New York
A state bill is a proposed law in a state legislature — separate from the U.S. Congress. Learn more →
Summary
This resolution requests that Governor Kathy Hochul proclaim June 9, 2026, as FSGS Awareness Day in New York State. FSGS (focal segmental glomerulosclerosis) is a progressive kidney disease characterized by scarring of the kidney's filtering units, affecting approximately 1 in 7 adults with chronic kidney disease. The resolution notes that about 50 percent of people diagnosed with FSGS require dialysis or kidney transplant within 5 to 10 years, and that the disease disproportionately affects African Americans due to genetic factors. The resolution also highlights recent progress in treatments, including FDA approval of a new therapy in April 2026 and ongoing clinical trials.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
- Gustavo Rivera Democratic · primary
Action history (3)
- May 6, 2026 REFERRED TO FINANCE · upper
- May 12, 2026 REPORTED TO CALENDAR FOR CONSIDERATION · upper
- May 12, 2026 ADOPTED · upper
Text versions (2)
Full text
Full text imported from assembly.state.ny.us
Skip to main content
New York State Assembly Speaker Carl E. Heastie
--> --> -->
Assembly Members
Legislative Info
Public Hearings
Speaker's Press
Assembly Reports
Committees & More
Bill Search Home Laws Legislative Calendar Public Hearing Schedule Assembly Calendars Assembly Committee Agenda Javascript must be enabled to properly view this page.
Bill No.: Summary Actions Committee Votes Floor Votes Memo Text LFIN Chamber Video/Transcript J02047 Summary: BILL NO J02047   SAME AS No Same As   SPONSOR RIVERA   COSPNSR   MLTSPNSR  
 
Go to top J02047 Text:
Senate Resolution No. 2047
BY: Senator RIVERA
MEMORIALIZING Governor Kathy Hochul to proclaim June 9, 2026, as FSGS Awareness Day in the State of New York
WHEREAS, Chronic kidney disease affects approximately 1 in 7 adults in the United States, and glomerulonephritis-often caused by rare kidney diseases such as focal segmental glomerulosclerosis (FSGS)-is among its leading causes; and
WHEREAS, FSGS is a serious and progressive disease characterized by scarring of the kidney's filtering units, frequently resulting in significant health complications, including kidney failure, the need for dialysis or transplantation, and cycles of remission and relapse; and
WHEREAS, Approximately 50 percent of individuals diagnosed with FSGS will require dialysis or a kidney transplant within 5 to 10 years; and
WHEREAS, Even following kidney transplantation, FSGS may recur in up to 50 percent of patients, underscoring the severity and persistence of this disease; and
WHEREAS, FSGS can affect individuals of all ages but is most commonly diagnosed in adults, particularly those over the age of 45; and
WHEREAS, Rare kidney diseases such as FSGS represent only a small percentage of chronic kidney disease cases, yet account for a disproportionately high percentage of kidney failure; and
WHEREAS, Patients living with FSGS often face significant delays in diagnosis, frequently enduring a diagnostic journey lasting several years, compounded by limited access to specialized nephrology care; and
WHEREAS, FSGS disproportionately impacts minority populations, including African Americans, in part due to genetic risk factors such as variants of the APOL1 gene, contributing to longstanding health disparities; and
WHEREAS, The burden of FSGS extends beyond individual patients and families, placing substantial strain on healthcare systems, including those serving the residents of the State of New York, and contributing to significant public and private healthcare expenditures; and
WHEREAS, There is new hope for patients with FSGS, with clinical trials underway for products that may delay progression of FSGS and the onset of kidney disease, including the first FDA approved therapy in April 2026, and significant progress being made by scientists, regulators, patient groups, and industry through the PARASOL Project to validate proteinuria as an indicator of improvement in patients; and
WHEREAS, In New York State, a diverse population and persistent health disparities make awareness, early detection, and equitable access to specialized care for rare kidney diseases especially critical; and
WHEREAS, New York is home to leading medical institutions, researchers, and patient advocacy organizations working to advance innovation, improve outcomes, and support those affected by rare kidney diseases such as FSGS; and
WHEREAS, Promising research and clinical trials are underway that may lead to new therapies capable of slowing disease progression and improving quality of life for patients with FSGS; and
WHEREAS, Patients, families, healthcare providers, researchers, and advocacy organizations-including NephCure Kidney International-are working diligently to raise awareness, promote early diagnosis, and expand access to effective treatments; and
WHEREAS, Designating FSGS Awareness Day will help increase public understanding of this rare disease, support those affected, and encourage continued investment in research and care; now, therefore, be it
RESOLVED, That this Legislative Body pause in its deliberations to memorialize Governor Kathy Hochul to proclaim June 9, 2026, as FSGS Awareness Day in the State of New York, and to recognize the importance of education, early detection, and continued research to improve outcomes for all those affected; and be it further
RESOLVED, That a copy of this Resolution, suitably engrossed, be transmitted to The Honorable Kathy Hochul, Governor of the State of New York.
Go to top
Sitemap
Request Information
Directions and Maps
Comments
Data from OpenStates. View on OpenStates →
Comments